Brainsway Ltd., which is developing a noninvasive medical device that treats brain-related disorders, withdrew its plans for an initial public offering on Tuesday. Roth Capital was set to be the lead underwriter on the deal.
Brainsway Ltd., which is developing a noninvasive medical device that treats brain-related disorders, withdrew its plans for an initial public offering on Tuesday. Roth Capital was set to be the lead underwriter on the deal.